Intrexon | XON - Interest Expense On Debt


Intrexon reported $2K in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Agenus USD 16.02M 2.85M Dec/2025
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Amgen USD 653M 32M Dec/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Incyte USD 582K 10K Dec/2025
Intrexon USD 2K 5K Jun/2024
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
MannKind USD 13.87M 6.54M Dec/2025
Merck USD 412M 85M Dec/2025
Novartis USD 304M 23M Dec/2025
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 365M 18M Dec/2025
Veracyte USD 2K 1000 Dec/2023
Xencor USD 7.35M 311K Dec/2025